RNA纳米医学在COVID-19大流行期间的显著影响证明了此领域在不同疾病背景下的广泛治疗潜力。近年来，以肝脏为靶点的RNA纳米医学已经在代谢性疾病如高草酸尿症和淀粉样变性的治疗中产生了革命性的影响。RNA纳米医学在肝脏疾病的管理中具有重要潜力，其中通过靶向递送、根据肝脏代谢调节剂量和基于特定感兴趣位置的个体化治疗能够获益。在本综述中，我们对在代谢紊乱相关的脂肪变性肝脏病、肝纤维化和肝癌等疾病中用于肝脏靶向的不同类型的RNA和纳米载体以及它们的具体应用进行了深入探讨。我们进一步强调了细胞特异性递送的策略以及小激活RNA、环状RNA和RNA碱基编辑方法出现后该领域研究的未来展望。版权所有 © 2023美国肝脏疾病研究协会。

The remarkable impact of RNA nanomedicine during the COVID-19 pandemic has demonstrated the expansive therapeutic potential of this field in diverse disease contexts. In recent years, RNA nanomedicine targeting the liver has been paradigm-shifting in the management of metabolic diseases such as hyperoxaluria and amyloidosis. RNA nanomedicine has significant potential in the management of liver diseases, where optimal management would benefit from targeted delivery, doses titrated to liver metabolism, and personalized therapy based on the specific site of interest. In this review, we discuss in-depth the different types of RNA and nanocarriers used for liver targeting along with their specific applications in metabolic dysfunction-associated steatotic liver disease, liver fibrosis, and liver cancers. We further highlight the strategies for cell specific delivery and future perspectives in this field of research with the emergence of small activating RNA, circular RNA and RNA base editing approaches.Copyright © 2023 American Association for the Study of Liver Diseases.